Kalydeco (ivacaftor)
pCPA File Number:
21106
Negotiation Status:
Concluded with an LOI
Indication(s):
cystic fibrosis in patients with CFTR gating mutations or the R117H gating mutation
Sponsor/Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded: